Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer

External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing

(2018) Kelly Dufraing et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Integrating liquid biopsies into the management of cancer

(2017) Giulia Siravegna et al.   Nature Reviews Clinical Oncology

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?

(2016) Riccardo Giampieri et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia

(2016) Koichi Oshima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia: Table 1.

(2016) Sydney X. Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer

(2015) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy

(2014) P. Laurent-Puig et al.   CLINICAL CANCER RESEARCH